DOCSLIB.ORG

Lentiviral Vectors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lentiviral Vectors RAC-Clinigene Meeting, Bethesda, Dec 2010 iget SAN RAFFAELE TELETHON INSTITUTE FOR GENE THERAPY Improving the Safety of HSC Gene Therapy by Targeting/De-targeting Gene Transfer Luigi Naldini M.D., Ph.D. San Raffaele Telethon Institute for Gene Therapy, Milan, Italy Improving the Safety of HSC Gene Therapy • Regulate transgene expression – Ectopic or constitutive expression may cause toxicity • Alleviate risk of insertional mutagenesis – Improve vector choice & design • Target integration to specific sites Regulate Transgene Expression • Stable gene transfer requires integration into HSC – Ectopic or constitutive transgene expression may cause toxicity – Target gene expression to mature cells or selected lineage Targeting Gene Transfer • Transcriptional targeting Select lineage-specific transcriptional control elements → Transgene expression directed to desired cell lineage Promoter Transgene mirT • Post-transcriptional targeting Incorporate miRNA target sequences into vector transcript → De-target from unwanted cell types Regulating Transgenes by Endogenous miRNAs RISC Dicer Drosha PGK GFPDNA mirT miRNA X DNAPGKGenomicGFP DNA mirT target sequences for miRNA X Mature Cells Stem/Progenitor Cells miRNAs in Hematopoietic Stem Cells • Little is known of miRNAs expressed in hematopoietic stem/progenitor cells (HSPC) • Expression profile data – bulk vs. pure populations – in rare cell populations • Functional activity – expression level vs. activity – in vivo studies From Landgraf et al. Cell 2007 Bidirectional miRNA-Regulated Vectors GA RRE Amendola et al, polyA ∆LNGFR PGK GFP WPRE Nat Biotech 2005 293T Kidney Cells U937 Monocytes 4 4 10 1% 99% 10 3% 96% x=5 x=4046 x=6 x=630 3 3 10 y=63 y=1503 10 y=191 y=1214 2 2 10 10 1 1 10 10 0 0 10 10 0 1 2 3 4 0 1 2 3 4 10 10 10 10 10 10 10 10 10 10 4 4 10 10 142-3pT 142-3pT 11% 83% 77% 1% 142-3pT 142-3pT Bd.LV.miRT x=5 x=235 x=4 x=16 3 3 y=186 y=1139 10 y=1092 y=1433 LNGFR 10 ∆ 2 2 10 10 1 1 10 10 0 0 10 10 0 1 2 3 4 0 1 2 3 4 Brown et al, Nat Med 2006 10 10 10 10 10 10 10 10 10 10 Brown, Gentner et al, Nat Biotech 2007 GFP Profiling miRNAs in Mouse HSPC GA RRE polyA NGFR PGK d4GFP WPRE miRT Ψ 126T 126T 126T 126T SD SA 223T 223T 223T 223T ...T ...T ...T ...T Ex vivo HS/PC Identify HS/PC by immunophenotyping transduction Transplant into conditioned mice Bone Marrow miRNAs Specific for HSC / Early Progenitors miRNAs in Human HSPC and LV Regulation Transduce human HSPC Read miRNA activity NGFR PGK GFP miRT (CD34+ cells from cord In HSPC After DIFF blood or bone marrow) (2 days post (in vitro transduction) culture) Ctr 126T 130aT 223T - l H S CD34+38 P C CD34+38+ + 3 D CD1 I F + 35 F 2 D miRNA activity (Fold repression) C miR-126 in Human HSP & Myeloid Cells NGFR PGK GFP NGFR PGK GFP 126T - 2 repeats CD34+38 GFP G-CSF CD34+38+ NGFR CFU-G/- Myeloblast Promyelocyte Myelocyte Metamyelocyte/Gr GM CD34int13+11b- CD34-13+11b- CD13+11b+16- CD13+11b+16+ CD34hi13+ GFP.126T NGFR Summary: miRNAs in HS/PC • Quantitative functional profile of miRNAs – miRNAs specifically active in human and murine HSPC identified • Exploit them to – Improve the safety of HSC gene therapy Gentner, Visigalli, Hiramatsu, Lechman et al., Science Transl. Med., 2010 Gene Therapy of Leukodystrophies Arylsulfatase A Galactocerebrosidase ARSA GALC SO2 GALACTO CEREBROSIDE SULFATIDE CEREBROSIDE (CERAMIDE) METACHROMATIC GLOBOID LEUKODYSTROPHY LEUKODYSTROPHY Transplantation of autologous LV-transduced, enzyme over-expressing HSC Toxicity of GALC over-expression in HSPC but NOT in differentiated progeny De-target expression from HSPC GALC Expression in HSPC is Limited by Toxicity Galc-/- HSPC Differentiated HC LV. GALC 120 100 0,12 + 80 0,1 /mg) 60 mU 0,08 TUNEL TUNEL 0,06 % 40 0,04 20 0,02 GALC activityGALC ( 0 0 GALC GALC.126T GFP.126T UT GALC GALC.126T GLD Gene Therapy by LV.126T Wild-type HSPC + LV.GFP Transplant into neonate Galc-/- HSPC + LV.GALC.126T GLD mice Prolonged survival Dose-effect relationship 100 200 ** UT -/- GALC-126T 175 75 +/+ GFP 150 125 50 100 75 25 50 25 0 0 0 50 100 150 200 250 <3 >3 Days Brain GALC activity (nmol/mg/h) Summary: miR-126 LV & GLD Gene Therapy • miR-126 regulated LV – Protect human and mouse HSPC from GALC toxicity – Enable HSC-based gene therapy of GLD in mouse model – Can be broadly used to improve safety of HSC gene therapy Gentner, Visigalli, Hiramatsu, Lechman et al., Science Transl. Med., 2010 Site-Specific Gene Insertion • Minimizes risk of insertional mutagenesis • Insertion downstream endogenous promoter – Restores function and endogenous expression control (gene correction) – Most mutations, including insertions and deletions can be corrected • Insertion into a safe genomic site – Robust predictable expression without perturbing endogenous transcription Designed Zinc Finger Nuclease (ZFN) ZFP ZFP . Contains two domains: . Nuclease domain of FokI restriction enzyme . Engineered Zinc Finger Protein (ZFP) . Cleaves DNA as a dimer . Can be engineered to cleave a pre-determined sequence Kim & Chandrasegaran, PNAS USA 1996; Porteus & Baltimore, Science 2003 Bibikova & Carroll, Science 2003; Urnov et al. Nature 2005 Exploiting ZFNs for Gene Targeting DNA DSB at ZFN target site no yes donor template NHEJ HDR Gene Disruption Transgene Insertion Lombardo et al., Nature Biotechnology 2007 Efficiency of Targeted Integration in Human Cells % Transgene Cell Type Target Site Positive Cell Lines (several types) ILR2G, CCR5, AAVS1 up to 60% Primary Fibroblasts CCR5, AAVS1 up to 11% Primary Keratinocytes CCR5 up to 5% Primary Lymphocytes CCR5, AAVS1 up to 5% Hematopoietic ILR2G, CCR5, AAVS1 up to 0.3% Stem/Progenitors ES Cell Lines ILR2G, CCR5 up to 5% iPS Cells CCR5, AAVS1 up to 1% Neuronal Stem Cells AAVS1 up to 15% A. Lombardo, P. Genovese, E. Provasi, C. Bonini, G. Maruggi, F. Mavilio, B. Di Stefano, M. Neri Summary: Gene Correction • Knock-in of IL2RG cDNA downstream endogenous promoter – normal γ-c expression • Gene correction coupled to selectable marker – in primary SCID-X1 patient’s fibroblasts • Reprogramming by single copy excisable LV Vector- and Reprogramming Factors-free, gene corrected iPSC Insertion into a Safe Genomic Site? • Choice of site not obvious – Gene desert vs. inter- or intra-genic – Info available mostly for transcribed genome • Knock-out of target locus must be well tolerated – Insertion may inactivate target gene – ZFNs may disrupt both alleles – Candidate Loci: CCR5, AAVS1 • Robust & predictable transgene expression • Lack of interference with expression of the flanking genes Summary: Assessing Safe Insertions in the Genome • Transcriptional perturbation – Upregulation of flanking genes depends on type - but not strength - of exogenous promoter – varies with the targeted locus – interference with transcription of targeted gene can be prevented by vector engineering • AAVS1 has desirable features – No deregulation of flanking genes even with strong promoter – Stable robust expression Lombardo et al., submitted Contributors: HSC miRNAs & GLD Gene Therapy San Raffaele Telethon Univ. Toronto, Ontario Institute for Gene Therapy Inst. for Cancer Res. John Dick Brian Brown iget Hidefumi Hiramatsu SAN RAFFAELE Bernhard Gentner TELETHON INSTITUTE FOR GENE THERAPY Alice Giustacchini Eric Lechman Massimo Saini Francesco Boccalatte Univ. Perugia Mario Amendola Sabata Martino Giulia Schira Aldo Orlacchio Lucia Sergi Sergi Alessandra Biffi European Research Council Ilaria Visigalli Advanced Grant Silvia Ungari Angelo Quattrini Contributors: Site-Specific Integration San Raffaele Telethon San Raffaele Institute Institute for Gene Therapy Milan, Italy Angelo Lombardo Chiara Bonini iget Pietro Genovese Elena Provasi SAN RAFFAELE TELETHON INSTITUTE FOR GENE THERAPY Pietro Lo Riso Vania Broccoli Daniela Cesana Bruno Distefano Eugenio Montini Sara Maffioletti Angela Gritti European Research Council Margherita Neri Advanced Grant Sangamo BioSciences NCTD, Heidelberg, FRG Richmond, CA Christof von Kalle Philip D. Gregory Manfred Schmidt Michael C. Holmes Richard Gabriel.
Load more

Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • Characterization of a Mutation in a Family with Saposin B Deficiency
    Proc. Nadl. Acad. Sci. USA Vol. 87, pp. 2541-2544, April 1990 Genetics Characterization of a mutation in a family with saposin B deficiency: A glycosylation site defect (sphingolipid activator protein/SAP-1/metachromatic leukodystrophy/arylsulfatase A) KEITH A. KRETZ*, GEOFFREY S. CARSON*, SATOSHI MORIMOTO*t, YASUO KISHIMOTO*, ARVAN L. FLUHARTYt, AND JOHN S. O'BPUEN*§ *Department of Neurosciences and Center for Molecular Genetics, University of California, San Diego, School of Medicine, M-034J, La Jolla, CA 92093; and tUniversity of California, Los Angeles, Mental Retardation Research Center Group at Lanterman Developmental Center, Pomona, CA 91766 Communicated by Dan L. Lindsley, January 19, 1990 ABSTRACT Saposins are small, heat-stable glycoproteins these four saposin proteins has now been isolated and their required for the hydrolysis of sphingolipids by specific lyso- activating properties have been determined (3-14). somal hydrolases. Saposins A, B, C, and D are derived by Saposins A and C specifically activate hydrolysis of glu- proteolytic processing from a single precursor protein named cocerebroside byB-glucosylceramidase (D-glucosyl-N-acyl- prosaposin. Saposin B, previously known as SAP-1 and sul- sphingosine glucohydrolase; EC 3.2.1.45) and ofgalactocere- fatide activator, stimulates the hydrolysis of a wide variety of broside by galactosylceramidase (D-galactosyl-N-acyl- substrates including cerebroside sulfate, GM1 ganglioside, and sphingosine galactohydrolase; EC 3.2.1.46) (3, 4). Saposin D globotriaosylceramide by arylsulfatase A, acid 8-galacto- specifically activates the hydrolysis of sphingomyelin by sidase, and a-galactosidase, respectively. Human saposin B sphingomyelin phosphodiesterase (sphingomyelin choline- deficiency, transmitted as an autosomal recessive trait, results phosphohydrolase; EC 3.1.4.12) (5).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • 2016 Mock Exam General Pathology Answer Sheet
    Name___________________________ 2016 Mock Exam General Pathology 1. You have 1 HOUR to complete this 50-question multiple choice exam. 2. Write your name on all pages of the exam packet. 3. Use capital letters on the answer sheet. 4. For each question, select the ONE best answer and mark it on the answer sheet. 5. Credit will be given only for correct answers recorded on the answer sheet. 6. All questions for which more than one answer is marked will be recorded as incorrect. 7. No credit will be awarded or deducted for incorrect answers. 8. Turn in the entire exam packet when you are done. 2016 Mock Exam General Pathology Answer sheet 1. ______ 26. ______ 2. ______ 27. ______ 3. ______ 28. ______ 4. ______ 29. ______ 5. ______ 30. ______ 6. ______ 31. ______ 7. ______ 32. ______ 8. ______ 33. ______ 9. ______ 34. ______ 10. ______ 35. ______ 11. ______ 36. ______ 12. ______ 37. ______ 13. ______ 38. ______ 14. ______ 39. ______ 15. ______ 40. ______ 16. ______ 41. ______ 17. ______ 42. ______ 18. ______ 43. ______ 19. ______ 44. ______ 20. ______ 45. ______ 21. ______ 46. ______ 22. ______ 47. ______ 23. ______ 48. ______ 24. ______ 49. ______ 25. ______ 50. ______ ii 2016 Mock Exam Name___________________________ General Pathology 1. Which of the following toxins reaches its target cell using retrograde axonal transport? a. tetanospasmin b. botulinum toxin c. syntaxin d. SNAP-25 2. All of the following EXCEPT which are true regarding high mobility group box protein 1 (HMGB-1)? a.
    [Show full text]
  • Structural Study of the Acid Sphingomyelinase Protein Family
    Structural Study of the Acid Sphingomyelinase Protein Family Alexei Gorelik Department of Biochemistry McGill University, Montreal August 2017 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Alexei Gorelik, 2017 Abstract The acid sphingomyelinase (ASMase) converts the lipid sphingomyelin (SM) to ceramide. This protein participates in lysosomal lipid metabolism and plays an additional role in signal transduction at the cell surface by cleaving the abundant SM to ceramide, thus modulating membrane properties. These functions are enabled by the enzyme’s lipid- and membrane- interacting saposin domain. ASMase is part of a small family along with the poorly characterized ASMase-like phosphodiesterases 3A and 3B (SMPDL3A,B). SMPDL3A does not hydrolyze SM but degrades extracellular nucleotides, and is potentially involved in purinergic signaling. SMPDL3B is a regulator of the innate immune response and podocyte function, and displays a partially defined lipid- and membrane-modifying activity. I carried out structural studies to gain insight into substrate recognition and molecular functions of the ASMase family of proteins. Crystal structures of SMPDL3A uncovered the helical fold of a novel C-terminal subdomain, a slightly distinct catalytic mechanism, and a nucleotide-binding mode without specific contacts to their nucleoside moiety. The ASMase investigation revealed a conformational flexibility of its saposin domain: this module can switch from a detached, closed conformation to an open form which establishes a hydrophobic interface to the catalytic domain. This open configuration represents the active form of the enzyme, likely allowing lipid access to the active site. The SMPDL3B structure showed a narrow, boot-shaped substrate binding site that accommodates the head group of SM.
    [Show full text]
  • A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism
    International Journal of Molecular Sciences Article A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism Aleksandra Poterala-Hejmo 1,*, Adam Golda 2 , Marcin Pacholczyk 1 , Sebastian Student 1, Anna Tylki-Szyma´nska 3 and Anna Lalik 1,* 1 Department of Systems Biology and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland; [email protected] (M.P.); [email protected] (S.S.) 2 Department of Cardiology, 4th Municipal Hospital, 44-100 Gliwice, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland; [email protected] * Correspondence: [email protected] (A.P.-H.); [email protected] (A.L.); Tel.: +48-32-2371168 (A.P.-H.); +48-32-2372769 (A.L.) Received: 2 June 2020; Accepted: 6 July 2020; Published: 12 July 2020 Abstract: Perturbations of glycosaminoglycan metabolism lead to mucopolysaccharidoses (MPS)—lysosomal storage diseases. One type of MPS (type VI) is associated with a deficiency of arylsulfatase B (ARSB), for which we previously established a cellular model using pulmonary artery endothelial cells with a silenced ARSB gene. Here, we explored the effects of silencing the ARSB gene on the growth of human pulmonary artery smooth muscle cells in the presence of different concentrations of dermatan sulfate (DS). The viability of pulmonary artery smooth muscle cells with a silenced ARSB gene was stimulated by the dermatan sulfate. In contrast, the growth of pulmonary artery endothelial cells was not affected. As shown by microarray analysis, the expression of the arylsulfatase G (ARSG) in pulmonary artery smooth muscle cells increased after silencing the arylsulfatase B gene, but the expression of genes encoding other enzymes involved in the degradation of dermatan sulfate did not.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Lab Dept: Chemistry Test Name: ARYLSULFATASE A, LEUKOCYTES
    Lab Dept: Chemistry Test Name: ARYLSULFATASE A, LEUKOCYTES General Information Lab Order Codes: ARYL Synonyms: Metachromic Leukodystrophy; Mucolipidoses, Types II and III; ARS-A (Arylsulfatase A); WBC Aryl Sulfatase A CPT Codes: 82657 – Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate Test Includes: Arylsulfatase A, Leukocyte level reported in nmol/h/mg. Logistics Test Indications: Leukocyte assay is the preferred test to order first to rule out metachromatic leukodystrophy. Not reliable in identifying carriers due both to analytical variation and unusual genetic variants. The urine assay should be used in confirming leukocyte results. Lab Testing Sections: Chemistry - Sendouts Referred to: Mayo Medical Laboratories (MML Test: ARSAW) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours (Specimen must be received by reference lab within 96 hours of collection and must be received 1 day prior to assay day for processing) Turnaround Time: 8 – 15 days; test set up Tuesday Special Instructions: Specimen must arrive within 48 hours of draw. Obtain special collection tube from the laboratory. Specimen Specimen Type: Whole blood Container: Yellow top (ACD Solution B) tube available from laboratory Alternate: Yellow top (ACD Solution A) Draw Volume: 6 mL (Minimum: 5 mL) ACD Whole blood Processed Volume: Same as Draw Volume Collection: Routine blood collection Special Processing: Lab Staff: Do Not process specimen, leave in original draw container.
    [Show full text]
  • Metachromatic Leukodystrophy Improved Diagnosis and Prognosis
    rJhlly /_ o I ME TACTIROMATIC LEUKODYS TR IMPROVED DIAGNOSIS ANI) PROGI{OSIS by Mohd Adi Firdaus TAN B.Biomedical Sc. (Hons) Department of Paediatrics The University of Adelaide Adelaide, South Australia This thesis is submitted for the degree of Doctor of Philosophy Date submitted: z8 March 2o,o,6 THESIS SUMMARY mole prevalent lysosomal storage Metachromatic leukodystrophy (MLD) is one of the births in Australia' The major cause of disorders with a reported incidence of I in 92,000 (ASA); this lysosomal enzyme, together this disease is the deficiency of arylsulphatase A of sulphatide' The with an activator protein, saposin B, is needed for the catabolism nervous system results in progressive subsequent accumulation of sulphatides in the central neurorogical function with a fatal outcome demyerination that reads to severe impairment of juvenile patients. for the more sevefely affected infantile and - l);. .1 MLD patients for more thanz' years' Bone marrow transprantation has been carried out in diffrcurt and remains a challenge However, successfur treatment of this disorder is often onset of neurological symptoms' At because patients are usually diagnosed after the in peripheral blood leucocltes present, MLD is diagnosed by measurement of ASA activity diagnosis is usually only obtained after and cultured skin fibroblasts. However, a definitive tests. The need for auxiliary tests is extensive testing with an arcay ofauxiliary laboratory (ASA-PD) mutation or ASA-PD/MLD' due to the presence of the ASA pseudo-deficiency low ASA enzyme activity' These which leads to clinically normal individuals who have conventional enzyme analysis; patients cannot be distinguished from MLD patients by MLD since saposin B deficiency is furthermore, normal enzyme activity cannot rule out also known to cause the disorder' and a simple skin fibroblast In this study, immune-based ASA activity and protein assays, a sulphatide quantification assay sulphatide-loading protocol, were developed.
    [Show full text]
  • Arylsulfatase G Inactivation Causes Loss of Heparan Sulfate 3-O-Sulfatase Activity and Mucopolysaccharidosis in Mice
    Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice Björn Kowalewskia, William C. Lamannab,1, Roger Lawrenceb,1, Markus Dammea,1, Stijn Stroobantsc, Michael Padvad, Ina Kalusa, Marc-André Fresea, Torben Lübkea, Renate Lüllmann-Rauche, Rudi D’Hoogec, Jeffrey D. Eskob, and Thomas Dierksa,2 aBiochemistry I, Department of Chemistry, Bielefeld University, 33615 Bielefeld, Germany; bDepartment of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093; cLaboratory of Biological Psychology, Department of Psychology, University of Leuven, 3000 Leuven, Belgium; dBiochemistry II, Georg-August University Göttingen, 37073 Göttingen, Germany; and eDepartment of Anatomy, Christian-Albrechts-University Kiel, 24098 Kiel, Germany Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved May 7, 2012 (received for review February 6, 2012) Deficiency of glycosaminoglycan (GAG) degradation causes a sub- Arylsulfatase G (ARSG), a recently characterized lysosomal sul- class of lysosomal storage disorders called mucopolysaccharidoses fatase with unknown physiological substrates (9), has been reported (MPSs), many of which present with severe neuropathology. Critical previously to be associated with an adult form of ceroid lipofuscinosis steps in the degradation of the GAG heparan sulfate remain enig- in dogs (10). In this study, we generated an ARSG-deficient mouse matic. Here we show that the lysosomal arylsulfatase G (ARSG) is model by targeted disruption of the Arsg gene.Inadditiontoheparan the long-sought glucosamine-3-O-sulfatase required to complete sulfate storage, we observed pathological changes common to MPS- fi the degradation of heparan sulfate.
    [Show full text]
  • Molecular Interactions Underlying Neuronal Ceroid Lipofuscinoses CLN1 and CLN5
    Annina Lyly Molecular Interactions Underlying Neuronal Ceroid Lipofuscinoses CLN1 and CLN5 Publications of the National Public Health Institute A 17/2008 Department of Molecular Medicine National Public Health Institute and Faculty of Medicine, University of Helsinki, Finland Helsinki, Finland 2008 Annina Lyly MOLECULAR INTERACTIONS UNDERLYING NEURONAL CEROID LIPOFUSCINOSES CLN1 AND CLN5 ACADEMIC DISSERTATION To be presented with the permission of the Medical Faculty of the University of Helsinki, for public examination in the Niilo Hallman lecture hall, Hospital for Children and Adolescents, Helsinki University Central Hospital, on June 6th , 2008, at 12 noon. National Public Health Institute, Helsinki, Finland and Faculty of Medicine, University of Helsinki, Finland Helsinki 2008 Publications of the National Public Health Institute KTL A17 / 2008 Copyright National Public Health Institute Julkaisija-Utgivare-Publisher Kansanterveyslaitos (KTL) Mannerheimintie 166 00300 Helsinki Puh. vaihde (09) 474 41, telefax (09) 4744 8408 Folkhälsoinstitutet Mannerheimvägen 166 00300 Helsingfors Tel. växel (09) 474 41, telefax (09) 4744 8408 National Public Health Institute Mannerheimintie 166 FIN-00300 Helsinki, Finland Telephone +358 9 474 41, telefax +358 9 4744 8408 ISBN 978-951-740-821-9 ISSN 0359-3584 ISBN 978-951-740-822-6 (pdf) ISSN 1458-6290 (pdf) Kannen kuva - cover graphic: Annina Lyly Yliopistopaino Helsinki 2008 Supervised by Adjunct Professor Anu Jalanko Department of Molecular Medicine National Public Health Institute, and Institute for Molecular Medicine Finland Helsinki, Finland Adjunct Professor Aija Kyttälä Department of Molecular Medicine National Public Health Institute, and Institute for Molecular Medicine Finland Helsinki, Finland Reviewed by Professor Pirjo Laakkonen Molecular Cancer Biology Program Faculty of Medicine University of Helsinki, and A.
    [Show full text]
  • Arylsulfatase a and the Campbell Family: a Molecular Story from the CBM
    Arylsulfatase A and the Campbell Family: a Molecular Story from the CBM I. The Campbell Family Background Lysosome III. The Role of Arylsulfatase A in Neurons V. Post-translational Modification Metachromatic Leukodystrophy } Aaron and Emily Campbell and their five children have lived all Glial cell Arylsulfatase Eukaryotic sulfatases carry an alpha-formylglycine residue that is (ASA) over the world calling countries like South America, South Africa Arysulfatase A (ASA) is a lysosomal essential for activity and is located within the catalytic site. Cysteine and India home. In 2011, the family began their journey in enzyme responsible for metabolizing sulfatides, 69 is post-translationally modified to Cα-formlyglycine. conquering another challenge. Victoria, the Campbell’s oldest sulfate-containing lipids found in the myelin SH daughter, began struggling in school accompanied by sheath that insulates neurons. Mutations in the Cerebroside O H coordination issues. An MRI revealed that Victoria suffered from 3-sulfate ARSA gene encoding ASA can result in a CH2 C brain damage due to a genetic disorder called juvenile onset defective enzyme, leading to the accumulation Formylglycine metachromatic leukodystrophy (MLD). A second daughter, NH2 - CH - CO NH2 - CH - CO of sulfatides in the lysosomes of myelin Generating Enzyme Madelena, was diagnosed a week later. After genetic testing of producing glial cells – oligodendrocytes in the 69 69 the remaining three children, the youngest son, Ike, was also central nervous system and Schwann cells in Non- diagnosed while Emma and Eli were determined to be carriers of Healthy the peripheral nervous system. Accumulation of functioning the disorder. ASA sulfatides leads to the death of these glial cells ASA and eventually to the demyelination of neurons.
    [Show full text]